PCSK6: The Endogenous PAR-1 Agonist Driving Pulmonary Fibrosis?-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

PCSK6: The Endogenous PAR-1 Agonist Driving Pulmonary Fibrosis?

Published:2023-06-15 Issue:12 Volume:207 Page:1643-1644
ISSN:1073-449X
Container-title:American Journal of Respiratory and Critical Care Medicine
language:en
Short-container-title:Am J Respir Crit Care Med

Author:

Spek C. Arnold¹²^ORCID,Duitman JanWillem³⁴⁵^ORCID

Affiliation:

1. Center for Experimental and Molecular Medicine,

2. Cancer Biology and Immunology, Cancer Center Amsterdam, Amsterdam, the Netherlands; and

3. Department of Pulmonary Medicine, and

4. Department of Experimental Immunology, Amsterdam UMC location University of Amsterdam, Amsterdam, the Netherlands;

5. Amsterdam Infection & Immunity, Inflammatory Diseases, Amsterdam, the Netherlands

Publisher

American Thoracic Society

Subject

Critical Care and Intensive Care Medicine,Pulmonary and Respiratory Medicine

Link

https://www.atsjournals.org/doi/pdf/10.1164/rccm.202303-0355LE

Reference6 articles.

1. PCSK6 and Survival in Idiopathic Pulmonary Fibrosis

2. Targeting protease activated receptor-1 with P1pal-12 limits bleomycin-induced pulmonary fibrosis

3. Vorapaxar proven to be a promising candidate for pulmonary fibrosis by intervening in the PAR1/JAK2/STAT1/3 signaling pathway-an experimental in vitro and vivo study

4. Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis

5. Neuroinflammation-Induced Interactions between Protease-Activated Receptor 1 and Proprotein Convertases in HIV-Associated Neurocognitive Disorder

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP